Suppr超能文献

精准医学:特发性肺纤维化的新前沿

Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.

作者信息

Brownell Robert, Kaminski Naftali, Woodruff Prescott G, Bradford Williamson Z, Richeldi Luca, Martinez Fernando J, Collard Harold R

机构信息

1 Department of Medicine, University of California San Francisco, San Francisco, California.

2 Department of Medicine, Yale University School of Medicine, New Haven, Connecticut.

出版信息

Am J Respir Crit Care Med. 2016 Jun 1;193(11):1213-8. doi: 10.1164/rccm.201601-0169CI.

Abstract

Precision medicine is defined by the National Institute of Health's Precision Medicine Initiative Working Group as an approach to disease treatment that takes into account individual variability in genes, environment, and lifestyle. There has been increased interest in applying the concept of precision medicine to idiopathic pulmonary fibrosis, in particular to search for genetic and molecular biomarker-based profiles (so called endotypes) that identify mechanistically distinct disease subgroups. The relevance of precision medicine to idiopathic pulmonary fibrosis is yet to be established, but we believe that it holds great promise to provide targeted and highly effective therapies to patients. In this manuscript, we describe the field's nascent efforts in genetic/molecular endotype identification and how environmental and behavioral subgroups may also be relevant to disease management.

摘要

美国国立卫生研究院精准医疗计划工作组将精准医疗定义为一种疾病治疗方法,该方法会考虑基因、环境和生活方式方面的个体差异。人们越来越有兴趣将精准医疗的概念应用于特发性肺纤维化,特别是寻找基于基因和分子生物标志物的特征(即所谓的内型),以识别机制上不同的疾病亚组。精准医疗与特发性肺纤维化的相关性尚待确定,但我们相信它极有可能为患者提供有针对性的高效治疗方法。在本手稿中,我们描述了该领域在基因/分子内型识别方面的初步努力,以及环境和行为亚组如何也可能与疾病管理相关。

相似文献

1
Precision Medicine: The New Frontier in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2016 Jun 1;193(11):1213-8. doi: 10.1164/rccm.201601-0169CI.
2
Idiopathic Pulmonary Fibrosis: Molecular Endotypes of Fibrosis Stratifying Existing and Emerging Therapies.
Respiration. 2017;93(6):379-395. doi: 10.1159/000475780. Epub 2017 May 5.
3
Precision medicine in idiopathic pulmonary fibrosis.
QJM. 2016 Sep;109(9):585-587. doi: 10.1093/qjmed/hcw117. Epub 2016 Aug 10.
5
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
Lancet Respir Med. 2014 Nov;2(11):933-942. doi: 10.1016/S2213-2600(14)70232-2. Epub 2014 Nov 3.
6
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI.
7
What if we made stratified medicine work for patients?
Lancet Respir Med. 2016 Jan;4(1):8-10. doi: 10.1016/S2213-2600(15)00499-3.
8
Precision medicine advances in idiopathic pulmonary fibrosis.
EBioMedicine. 2023 Sep;95:104766. doi: 10.1016/j.ebiom.2023.104766. Epub 2023 Aug 23.
9
What's New in Idiopathic Pulmonary Fibrosis?
Arch Bronconeumol (Engl Ed). 2018 Jan;54(1):1-2. doi: 10.1016/j.arbres.2017.06.020. Epub 2017 Jul 27.

引用本文的文献

2
Molecular Endotypes of Idiopathic Pulmonary Fibrosis: A Latent Class Analysis of Two Multicenter Observational Cohorts.
Am J Respir Crit Care Med. 2024 Aug 15;210(4):455-464. doi: 10.1164/rccm.202402-0339OC.
3
Genetic variations in idiopathic pulmonary fibrosis and patient response to pirfenidone.
Heliyon. 2023 Jul 24;9(8):e18573. doi: 10.1016/j.heliyon.2023.e18573. eCollection 2023 Aug.
5
The role of precision medicine in interstitial lung disease.
Eur Respir J. 2022 Sep 7;60(3). doi: 10.1183/13993003.02146-2021. Print 2022 Sep.
7
Lung Myofibroblasts Promote Macrophage Profibrotic Activity through Lactate-induced Histone Lactylation.
Am J Respir Cell Mol Biol. 2021 Jan;64(1):115-125. doi: 10.1165/rcmb.2020-0360OC.
8
Parametric Time-to-Event Model for Acute Exacerbations in Idiopathic Pulmonary Fibrosis.
CPT Pharmacometrics Syst Pharmacol. 2020 Feb;9(2):87-95. doi: 10.1002/psp4.12485. Epub 2020 Jan 25.
9
Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).
J Thorac Dis. 2019 Sep;11(Suppl 14):S1740-S1754. doi: 10.21037/jtd.2019.04.62.
10
Fibrosing interstitial lung diseases: knowns and unknowns.
Eur Respir Rev. 2019 Feb 27;28(151). doi: 10.1183/16000617.0100-2018. Print 2019 Mar 31.

本文引用的文献

1
Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis.
Lancet Respir Med. 2016 May;4(5):381-9. doi: 10.1016/S2213-2600(16)00067-9. Epub 2016 Mar 31.
2
What if we made stratified medicine work for patients?
Lancet Respir Med. 2016 Jan;4(1):8-10. doi: 10.1016/S2213-2600(15)00499-3.
3
Personalizing Therapy in Idiopathic Pulmonary Fibrosis: A Glimpse of the Future?
Am J Respir Crit Care Med. 2015 Dec 15;192(12):1409-11. doi: 10.1164/rccm.201509-1789ED.
4
TOLLIP, MUC5B, and the Response to N-Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2015 Dec 15;192(12):1475-82. doi: 10.1164/rccm.201505-1010OC.
5
Precision medicine: Beyond the inflection point.
Sci Transl Med. 2015 Aug 12;7(300):300ps17. doi: 10.1126/scitranslmed.aaa9970.
6
Personalized medicine in idiopathic pulmonary fibrosis: facts and promises.
Curr Opin Pulm Med. 2015 Sep;21(5):470-8. doi: 10.1097/MCP.0000000000000187.
7
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies.
Thorax. 2015 Aug;70(8):748-56. doi: 10.1136/thoraxjnl-2014-206719. Epub 2015 May 22.
8
Targeted therapy for lung cancer: present and future.
Ann Palliat Med. 2014 Jul;3(3):229-35. doi: 10.3978/j.issn.2224-5820.2014.06.01.
10
αvβ6 integrin may be a potential prognostic biomarker in interstitial lung disease.
Eur Respir J. 2015 Aug;46(2):486-94. doi: 10.1183/09031936.00210414. Epub 2015 Mar 5.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验